|
Diet
Rich in Foods with Vitamin E
May Reduce Alzheimer's Disease Risk |
A new population-based study of
antioxidants, appearing in the June 26, 2002, Journal of the American
Medical Association (JAMA), suggests that a diet rich in foods
containing vitamin E may help protect some people against Alzheimer's
disease (AD). The study is also noteworthy for its finding that vitamin E
in the form of supplements was not associated with a reduction in the risk
of AD. The latest in a series of reports on vitamin E and dementia, the
study findings heighten interest in the outcome of clinical trials now
underway to test the effectiveness of vitamin E and other antioxidants in
preventing or postponing cognitive decline and AD.
The JAMA study was conducted by
Martha Clare Morris, Sc.D., of the Rush Institute for Healthy Aging at
Rush-Presbyterian-St.Luke's Medical Center, Chicago, IL, Denis A. Evans,
M.D., and colleagues. A related study by Morris and colleagues, in
press in the July 2002 Archives of Neurology, a JAMA
publication, also associates vitamin E with protection against more
general cognitive decline. (Reporting of additional detail on this study
is embargoed for July 14, 2002, 4 p.m. ET.) Both studies were supported by
the National Institute on Aging (NIA) at the National Institutes of
Health.
The June 26 issue of JAMA includes
similar findings from scientists in The Netherlands, who also reported a
link between high dietary intake of vitamins C and E and protection
against AD in certain people. In addition, the journal contains an
editorial on the epidemiological study of dietary intake of antioxidants
and the risk of AD by Daniel J. Foley, M.S., of the NIA's Laboratory of
Epidemiology, Demography, and Biometry, and Lon White, M.D., Pacific
Health Research Institute, Honolulu.
"This and a number of important
population studies have pointed to vitamin E as possibly protective
against oxidative damage or other mechanisms associated with cognitive
decline and dementia," says Neil Buckholtz, Ph.D., head of the
Dementias of Aging Branch at the NIA. "The only way this association
can really be tested is through clinical studies and trials now underway.
These will help us determine whether vitamin E in food or in supplements
or taken together can prevent or slow down the development of mild
cognitive impairment or AD."
It is not recommended, based on current
evidence, that people take high-dose vitamin E supplements or other
antioxidant pills in an effort to prevent mental decline, Buckholtz says.
While population-based studies and animal research have suggested that
antioxidants may be neuroprotective, clinical trials to test that notion
are currently in progress. Little is known about safety, effectiveness,
and dosages of various antioxidant supplements that are proposed for
neuroprotective purposes, Buckholtz emphasizes. In excessively high doses
(above 2,000 International Units daily, or IU/d), for example, vitamin E
may be associated with increased risk of bleeding, and patients taking
anti-coagulant medications may be especially at risk. Interactions with
other medications commonly taken by older people are also of potential
concern. People are advised to consult with their physicians before taking
high doses of supplemental vitamin E or other antioxidants.
The 815 people participating in the
Morris study were part of the Chicago Health and Aging Project (CHAP), a
study of a large, diverse community of people age 65 and older.
Participants were free of dementia at the start of the study and followed
for an average of 3.9 years. At an average of 1.7 years from their
baseline assessment, participants completed a questionnaire, asking them
in detail about the kinds and quantities of foods consumed in the previous
year.
Some 131 participants had been diagnosed
with AD by the end of the study period, when researchers examined the
relationship between intake of antioxidants, including dietary and
supplemental vitamins E and C, beta carotene, and a multivitamin, and
development of AD. The most significant protective effect was found among
people in the top fifth of dietary vitamin E intake (averaging 11.4 IU/d),
whose risk of AD was 67 percent lower when compared to people in the group
with the lowest vitamin E consumption from food (averaging 6.2 IU/d). (The
recommended dietary allowance of vitamin E is 22 IU/d.) No significant
change in risk of AD was found when the scientists looked at vitamin E
supplements, the other antioxidants and their supplements, or a general
multivitamin. There was some evidence, though not statistically
significant, that increased intake of dietary vitamin C and beta carotene
was moving in a "protective direction," the researchers said.
The data were also analyzed to see if
age, gender, race, education, or possible genetic risk for AD would
influence the findings. Only the presence or lack of apoE-e4, one form of
a protein associated with increased risk of late-onset AD, seemed to
matter: the protective effect of vitamin E from food was strongest among
people who did not have the apoE-e4 risk factor allele. "Dietary
vitamin E may protect against Alzheimer's disease," says Morris,
"but the protection may only occur among people without the apoE-e4
allele."
Morris suggests that further study in key
areas is needed to confirm and explain some of the study's findings,
including the link with apoE status and the study's striking distinction
between dietary intake of vitamin E and use of supplements. For example,
the lack of a protective effect for the supplements could be explained by
several factors. Some participants in the study started taking supplements
only recently and there may not have been sufficient time for the
supplement to be found effective. Also, people who believe they have
memory problems could be more likely to take the supplements in the first
place. Another possible explanation might be variations in the forms of
vitamin E, scientists note. Most vitamin E supplements consist of alpha
tocopherol while foods are generally more rich in gamma tocopherol. These
forms of vitamin E scavenge different types of free radicals, with one
possibly more important than another in potentially reducing risk of
cognitive decline. To help determine whether vitamin E might play a role
in preventing AD, or at least in delaying its onset, a number of clinical
trials are now being supported by the NIA. These include:
 | Memory Impairment Study
This study targets people with mild cognitive impairment, or MCI,
testing the usefulness of vitamin E and donepezil to slow or stop the
conversion from MCI to AD. (Study has completed recruitment.)
Principal investigator: Dr. Ronald Petersen, Mayo Clinic, Rochester,
MN. |
 | Prevention of AD by Vitamin E and
Selenium (PREADVISE) An add-on to the National Cancer
Institute's Selenium and Vitamin E Prostate Cancer Prevention Trial
(SELECT), this investigation is testing vitamin E and selenium in
healthy men age 60 and older for preventing cognitive decline and AD.
(Some study sites have begun recruitment and others will begin
enrolling participants over the next few months. See below on
obtaining more information from NIA's ADEAR Center.) Principal
investigator: Dr. William Markesberry, University of Kentucky. |
 | Women's Antioxidant Cardiovascular
Study (WACS) Testing vitamin E, vitamin C, beta carotene, and
folate for slowing cognitive decline in women age 65 and older at high
risk of cardiovascular disease, the WACS is funded by the National
Heart, Lung, and Blood Institute (NHLBI). An add-on for cognitive
testing is supported by the NIA. (Recruitment and some cognitive
testing of participants have been completed.) Principal investigator:
Dr. Francine Grodstein, Harvard University. |
 | Women's Health Study (WHS)
Testing aspirin and vitamin E in healthy women age 65 and older for
slowing cognitive decline, the WHS is supported by the NHLBI and the
National Cancer Institute. An add-on for the cognitive studies is
supported by the NIA. (Recruitment and some cognitive testing of
participants have been completed.) Principal investigator: Dr.
Francine Grodstein, Harvard University. |
 | Physician's Health Study II (PHS
II) Testing beta carotene, vitamin E, vitamin C and
multivitamin with folate in healthy men age 65 and older for slowing
cognitive decline. NIA supports the cognitive supplement to this
privately funded study. (Recruitment and baseline cognitive testing of
participants have been completed.) Principal investigator: Dr.
Francine Grodstein, Harvard University. |
More information on these studies, as it
becomes available, will appear on the NIA-supported Alzheimer's Disease
Education and Referral (ADEAR) Center Web site at www.alzheimers.org.
The ADEAR Center also provides general information on AD research for
health professionals, the media, and the general public. ADEAR can be
contacted weekdays, toll free, at 1-800-438-4380.
The NIA leads the Federal effort
supporting and conducting biomedical, clinical, social, and behavioral
research on aging and on Alzheimer's disease specifically. Press releases,
fact sheets, and other materials about aging and aging research can be
viewed at the NIA's general information Web site, www.nia.nih.gov.
The National Institute on Aging is a
component of the National Institutes of Health, U.S. Department of Health
and Human Services.
|
|